News & Topics
News&Topics

2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2013.12.18
Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study
2013.12.10
Onconova Presents Phase 2 Data for Oral Rigosertib at 2013 American Society of Hematology Annual Meeting
2013.11.27
SymBio Announces Pricing of Secondary Offering and Overallotment
2013.11.19
SymBio Announces Issuance of New Shares and Secondary Offering of Shares
2013.11.14
Onconova Therapeutics, Inc. Reports Third Quarter 2013 Financial and Operational Results
2013.11.08
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-Consolidated)
2013.11.01
TREAKISYM® PhaseⅡ Trial in Multiple Myeloma
2013.10.18
Dr. George Morstyn (outside Board Director) has been elected a fellow of ATSE (The Australian Academy of Technological Sciences and Engineering).
2013.08.07
Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-Consolidated)
2013.07.26
SymBio Announces Revised Financial Forecast
2013.06.03
Onconova Presents Phase II Data for Oral Rigosertib at 2013 American Society of Clinical Oncology Annual Meeting - Oral Rigosertib (ON 01910.Na) in Transfusion-Dependent Lower Risk MDS
2013.05.14
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-consolidated)
2013.05.10
Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes
2013.05.08
SymBio Initiates Japanese Phase II Trial for TREAKISYM® (Bendamustine) in CLL
2013.05.07
JCO (Journal of Clinical Oncology)- Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2013.03.28
Dr. Milton H. Grannatt Joins SymBio as Outside Director
2013.03.26
SymBio Initiates Japanese Phase I Trial of Oral rigosertib (SyB C-1101) in Frontline MDS
2013.03.15
SYMBIO AND EISAI ANNOUNCE REMOVAL OF TREAKISYM® INJECTION 100 MG ALL CASES SURVEILLANCE CONDITION FOR JAPAN MARKETING APPROVAL
2013.03.06
Completion of Patient Enrollment of TREAKISYM® (SyB L-0501) Phase II Trial in Frontline Low-grade Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma
2013.02.20
The Lancet(Online First) - Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013.02.14
Summary of Financial Statements for the Fiscal Year Ended December 31, 2012 [Japanese GAAP] (Non-consolidated)
2013.01.28
SymBio Completes Phase 2 Trial of Antiemetic Transdermal Patch (SyB D-0701) in RINV
2013.01.07
SymBio Receives Clinical Trial Notification Acceptance for Phase 2 TREAKISYM® (Bendamustine) Trial in CLL